⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCGN News
Ocugen, Inc. Common Stock
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
globenewswire.com
OCGN
Form 8-K
sec.gov
OCGN
Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
AXSM
VRTX
RLMD
VSTA
PRAX
NBIX
ALTO
LLY
JNJ
MRK
ABBV
BMY
REGN
BIIB
ANVS
ALEC
LEXX
COYA
NVO
IONQ
NVDA
AMD
INTC
GOOG
MSFT
AMZN
TSLA
AAPL
META
IBM
CRM
ADBE
NFLX
CMCSA
VZ
T
KO
PEP
MCD
DIS
BA
CAT
GE
XOM
CVX
JPM
BAC
WFC
GS
MS
V
MA
HD
WMT
COST
PG
PFE
MRNA
GILD
AMGN
NVS
TAK
EXAS
CRSP
EDIT
NTLA
INCY
ALKS
ACAD
AZN
TEVA
BHC
LULU
UBER
LYFT
SPCE
PLTR
SNOW
DDOG
CRWD
ZS
PANW
FTNT
NOW
ADSK
MCHP
NXPI
ON
QCOM
MU
WDC
SE
MELI
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
NIO
XPEV
LI
RIVN
LCID
PLUG
FCEL
BE
SPWR
ENPH
SEDG
RUN
NEO
CLSK
CRBU
RXRX
DTIL
ADPT
CYTK
IMUX
MNKD
SRPT
BNTX
RVMD
ACRS
EXEL
FGEN
GNTX
HRMY
INSM
ITRM
KODK
LPCN
NCLH
OCGN
ORGO
PACB
PBYI
PEGA
PLRX
PRGS
PTON
PYPL
QGEN
QRVO
RDNT
REPL
ROKU
RYAAY
SAVA
SBAC
SCLX
SDRL
SEIC
SIRI
SMCI
SNPS
SOFI
SPOT
SSYS
STX
SWKS
SYK
TCOM
TEAM
TER
TGT
TMO
TMUS
TXN
UAL
ULTA
UPS
VRSK
WDAY
XEL
XYL
ZBRA
Coave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the Clinic
globenewswire.com
OCGN
PFE
Form 8-K
sec.gov
OCGN
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
globenewswire.com
OCGN
Ocugen to Participate in Upcoming September Investor and Industry Conferences
globenewswire.com
OCGN
Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
prnewswire.com
ACRS
ALC
AMGN
BCRX
BIIB
BMY
CRSP
CTRA
CYTK
DASH
EXAS
GILD
GSK
INCY
JNJ
KDP
LULU
MRNA
NBIX
NVS
OCGN
ORCL
PFE
REGN
ROST
RVMD
SNOW
SRPT
STRL
TGTX
TMO
TRMB
TSLA
TXG
VRTX
XOM
ZBRA
Alma Global Consultants CEO Dr. Huma Qamar Reflects on a Journey Through Medicine, Biotechnology and Clinical Research
accessnewswire.com
OCGN
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL